IL325801A - טיפול בחוסר אלפא-1 אנטיטריפסין - Google Patents

טיפול בחוסר אלפא-1 אנטיטריפסין

Info

Publication number
IL325801A
IL325801A IL325801A IL32580126A IL325801A IL 325801 A IL325801 A IL 325801A IL 325801 A IL325801 A IL 325801A IL 32580126 A IL32580126 A IL 32580126A IL 325801 A IL325801 A IL 325801A
Authority
IL
Israel
Prior art keywords
therapy
alpha
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
IL325801A
Other languages
English (en)
Original Assignee
Precigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc filed Critical Precigen Inc
Publication of IL325801A publication Critical patent/IL325801A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
IL325801A 2023-07-10 2024-07-10 טיפול בחוסר אלפא-1 אנטיטריפסין IL325801A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363512773P 2023-07-10 2023-07-10
PCT/US2024/037285 WO2025014986A2 (en) 2023-07-10 2024-07-10 Therapy for alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
IL325801A true IL325801A (he) 2026-03-01

Family

ID=94216330

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325801A IL325801A (he) 2023-07-10 2024-07-10 טיפול בחוסר אלפא-1 אנטיטריפסין

Country Status (6)

Country Link
KR (1) KR20260042173A (he)
CN (1) CN121909290A (he)
AU (1) AU2024288666A1 (he)
IL (1) IL325801A (he)
MX (1) MX2026000042A (he)
WO (1) WO2025014986A2 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025155772A1 (en) * 2024-01-19 2025-07-24 Gene Company (Pty)Ltd. Alpha-1 anti-trypsin upregulating polynucleotides and method of use and treatment thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CN114072500B (zh) * 2019-08-02 2024-05-10 香港科技大学 控制microRNA表达的方法
AU2022205683A1 (en) * 2021-01-11 2023-07-06 Precigen, Inc. Chimeric receptor therapy

Also Published As

Publication number Publication date
KR20260042173A (ko) 2026-03-30
MX2026000042A (es) 2026-02-03
WO2025014986A3 (en) 2025-03-20
CN121909290A (zh) 2026-04-21
WO2025014986A2 (en) 2025-01-16
AU2024288666A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
CA3280142A1 (en) Compounds for treating alpha-1 antitrypsin-mediated diseases
IL282237A (he) תכשירים ושיטות לטיפול בחוסר אלפא-1 אנטיטריפסין
HUE064089T2 (hu) Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
IL325801A (he) טיפול בחוסר אלפא-1 אנטיטריפסין
IL318884A (he) מודולטורים של אלפא-1 אנטיטריפסין
CA216491S (en) Controller
IL325521A (he) בודיודרון לטיפול בהיפוך לב
GB202212144D0 (en) Cells for therapy
CA3297720A1 (en) Therapy for alpha-1 antitrypsin deficiency
IL312033A (he) הרכבים ושיטות לטיפול בחוסר אלפא-1 אנטיטריפסין
HK40083723A (en) Methods of treatment for alpha-1 antitrypsin deficiency
CA3261397A1 (en) POLYTHERAPY
HK40115697A (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
HK40066512A (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
CA3293811A1 (en) Methods and compositions for treating alpha-1 antitrypsin deficiency
CA230440S (en) Controller
CA3305693A1 (en) Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders
HK40109562A (en) Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
HK40109230A (en) Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
CA232169S (en) Controller
CA231442S (en) Controller
CA229583S (en) Controller
CA238703S (en) Irrigation controller
CA219515S (en) Lateral left access fitting
GB202202995D0 (en) Controller